BridgeBio Pharma, Inc. (BBIO) — Stock Score Summary

BridgeBio Pharma, Inc. (BBIO) has a MoatMap StockRank of 51/100 based on Quality (31/100), Value (48/100), and Momentum (58/100) factor scores. The current signal is HOLD. BridgeBio is a clinical-stage drug developer that faces binary clinical trial risks and is a potential casualty of rising CDMO manufacturing costs.

BridgeBio Pharma, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing medicines for genetic diseases and genetically driven cancers. Its competitive edge stems from a diversified portfolio of therapeutic candidates across various indications and a unique "hub-and-spoke" R&D model designed to efficiently advance programs. The company aims to address significant unmet medical needs through a precision medicine approach.

Key Financial Metrics

Price$67.79
Market Cap$13.4B
P/E (Forward)203.15
Price/Book-5.78
Return on Invested Capital-85.5%
Gross Margin95.1%
Operating Margin-54.5%
Revenue Growth66.8%
Free Cash Flow$-318M

BridgeBio Pharma, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is BridgeBio Pharma, Inc.’s (BBIO) StockRank?
MoatMap’s StockRank for BridgeBio Pharma, Inc. (BBIO) is 51/100, with a Hold signal. It is a composite of Quality (31), Value (48), and Momentum (58) factor ranks across MoatMap’s 19,000+ stock universe.
Does BridgeBio Pharma, Inc. have an economic moat?
BridgeBio Pharma, Inc. (BBIO) has a Quality factor score of 31/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is BridgeBio Pharma, Inc. a buy, hold, or sell?
MoatMap’s current signal for BridgeBio Pharma, Inc. (BBIO) is Hold, based on a StockRank of 51/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is BridgeBio Pharma, Inc. in?
BridgeBio Pharma, Inc. (BBIO) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksBBIO deep dive reportAI ChampionsHow we score stocksSense-check another stock